Aldeyra Therapeutics, Inc. · NASDAQ:ALDX
Aldeyra Therapeutics — Technical Presentation (June 2017)
13 slides from Aldeyra Therapeutics's technical presentation, Jun 14, 2017
Slide 1: Allergic Conjunctivitis Phase 2b Results
Allergic Conjunctivitis Phase 2b Results June 14, 2017 Exhibit 99.1
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended
Slide 3: Key Conclusions
Allergic Conjunctivitis Phase 2b Key Conclusions The results confirm the activity of ADX-102 in allergic conjunctivitis. Aldeyra plans to move forward aggressively to Phase 3 testing. Aldeyra believes that the differentiated clinical response to ADX-102 supports a compelling product opportunity in a
Slide 4: Clinical Design
Allergic Conjunctivitis Phase 2b Clinical Design Groups Topical Ocular ADX-102 0.1%, ADX-102 0.5%, or Vehicle Randomization Double-Masked, Vehicle-Controlled 1:1:1 Enrollment 154 Patients with History of Allergic Conjunctivitis Model Single Dose Seasonal and Perennial Allergen Challenge Endpoint Pat
Slide 5: Histamine and Non-Histamine Components of Itch Score After Allergen Challenge
Histamine and Non-Histamine Components of Itch Score After Allergen Challenge
Slide 6: Itch Score vs. Time Post-Challenge (Seasonal and Perennial Allergens)
Phase 2b Itch Score vs. Time Post-Challenge (Seasonal and Perennial Allergens) p values are subject to change based on quality control analysis.
Slide 7: Itch Score vs. Time Post-Challenge (Seasonal Allergens)
Phase 2b Itch Score vs. Time Post-Challenge (Seasonal Allergens) p values are subject to change based on quality control analysis.
Slide 8: Itch Score vs. Time Post-Challenge (Seasonal Allergens)
Phase 2b Itch Score vs. Time Post-Challenge (Seasonal Allergens) 1-point reduction at 5 minutes = -38% p values are subject to change based on quality control analysis.
Slide 9: Itch Score Frequency
Phase 2b Itch Score Frequency p values are subject to change based on quality control analysis.
Slide 10: Proportion of Subjects with Itch Scores of Less Than One
Phase 2b Proportion of Subjects with Itch Scores of Less Than One p values are subject to change based on quality control analysis.
Slide 11: Clinical Trial Summary
Allergic Conjunctivitis Phase 2b Clinical Trial Summary One-point itch score reduction vs. control (a component of the primary endpoint of all allergen challenge allergic conjunctivitis trials to date) was not met, but approached in seasonal allergy patients (peak reduction of 0.8). 0.5% ADX-102 was
Slide 12: A Common Unmet Medical Need
Allergic Conjunctivitis: A Common Unmet Medical Need Allergic conjunctivitis is estimated to affect 20% or more of worldwide population Symptoms include stinging, burning, tearing, pain, itching, redness Aldehydes may mediate IL-5 release and other pro-allergy cytokines An estimated 30 % - 40% of pa
Slide 13: Key Conclusions
Allergic Conjunctivitis Phase 2b Key Conclusions The results confirm the activity of ADX-102 in allergic conjunctivitis. Aldeyra plans to move forward aggressively to Phase 3 testing. Aldeyra believes that the differentiated clinical response to ADX-102 supports a compelling product opportunity in a
Aldeyra Therapeutics — Technical Presentation (June 2017) on 6ix